Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia
Xiaoyang Hua, … , Stephen Tilley, Stanley Perlman
Xiaoyang Hua, … , Stephen Tilley, Stanley Perlman
Published June 7, 2018
Citation Information: JCI Insight. 2018;3(11):e99025. https://doi.org/10.1172/jci.insight.99025.
View: Text | PDF
Research Article Immunology Virology

Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia

  • Text
  • PDF
Abstract

The nasal mucosa is an important component of mucosal immunity. Immunogenic particles in inspired air are known to activate the local nasal mucosal immune system and can lead to sinonasal inflammation; however, little is known about the effect of this activation on the lung immune environment. Here, we showed that nasal inoculation of murine coronavirus (CoV) in the absence of direct lung infection primes the lung immune environment by recruiting activated monocytes (Ly6C+ inflammatory monocytes) and NK cells into the lungs. Unlike infiltration of these cells into directly infected lungs, a process that requires type I IFN signaling, nasally induced infiltration of Ly6C+ inflammatory monocytes into the lungs is IFN-I independent. These activated macrophages ingested antigen and migrated to pulmonary lymph nodes, and enhanced both innate and adaptive immunity after heterologous virus infection. Clinically, such nasal-only inoculation of MHV-1 failed to cause pneumonia but significantly reduced mortality and morbidity of lethal pneumonia caused by severe acute respiratory syndrome CoV (SARS-CoV) or influenza A virus. Together, the data indicate that the nose and upper airway remotely prime the lung immunity to protect the lungs from direct viral infections.

Authors

Xiaoyang Hua, Rahul Vijay, Rudragouda Channappanavar, Jeremiah Athmer, David K. Meyerholz, Nitin Pagedar, Stephen Tilley, Stanley Perlman

×

Figure 7

Migration of Ly6C+ IMs.

Options: View larger image (or click on image) Download as PowerPoint
Migration of Ly6C+ IMs.
(A–C) CCR7 expression on Ly6C+ IMs. (A) Flow cyt...
(A–C) CCR7 expression on Ly6C+ IMs. (A) Flow cytometric plots showing increased CCR7+Ly6+ IM levels in mice after nasal-only inoculation. (B and C) Frequencies of CCR7+Ly6+ IMs in the lungs of mice with and without nasal infection. **P < 0.01; *P < 0.05. n = 5–6 per group. (D) Migration of Ly6+ IMs into the MLNs. BALB/c mice were intranasally infected with MHV-1 (2 μl, 104 PFU) or vehicle. Two days later, FITC-OVA was instilled IT. MLNs were then collected to evaluate cell migration. Data are representative of 2 independent experiments. (D) Flow cytometric plots showing increased frequency of FITC-OVA+Ly6C+ IMs in the MLNs. (E and F) Frequencies and numbers of FITC-OVA+Ly6C+ IMs in the MLNs collected from mice with and without intranasal infection. **P < 0.01 vs. controls. n = 3 per group.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts